Elektrofi Overview
- Year Founded
-
2016
- Status
-
Acquired/Merged
- Employees
-
96
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$810M
Elektrofi General Information
Description
Developer of a drug delivery platform designed to enhance subcutaneous administration. The company's platform supports complex proteins such as monoclonal antibodies, bispecifics, and fusion proteins with stable processing, enabling drug manufacturers to create advanced therapies while giving patients control over how they receive treatment.
Contact Information
Website
www.elektrofi.com(Operating Subsidiary)
Corporate Office
- 25 Drydock Avenue
- Second Floor
- Boston, MA 02210
- United States
Corporate Office
- 25 Drydock Avenue
- Second Floor
- Boston, MA 02210
- United States
Elektrofi Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 18-Nov-2025 | $810M | Completed | Generating Revenue | ||
| 7. Later Stage VC (Series C) | 08-Aug-2024 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series B) | 06-Jun-2022 | Completed | Generating Revenue | |||
| 5. Grant | 01-Jan-2021 | Completed | Generating Revenue | |||
| 4. Debt - PPP | 13-Apr-2020 | Completed | Generating Revenue | |||
| 3. Grant | 10-Sep-2018 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A1) | 13-Jul-2018 | $1.5M | $4M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 01-Jun-2018 | $2.5M | $2.5M | Completed | Generating Revenue |
Elektrofi Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A-1 | 980,681 | $0.000100 | 8% | $1.53 | $1.53 | 1x | $1.53 | 2.5% |
| Series A | 1,826,348 | $0.000100 | 8% | $1.14 | $1.14 | 1x | $1.14 | 4.66% |
Elektrofi Comparisons
Industry
Financing
Details
Elektrofi Competitors (32)
One of Elektrofi’s 32 competitors is Entos Pharmaceuticals, a Venture Capital-Backed company based in Edmonton, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Entos Pharmaceuticals | Venture Capital-Backed | Edmonton, Canada | ||||
| Lisata Therapeutics | Corporation | Basking Ridge, NJ | ||||
| Parion Sciences | Venture Capital-Backed | Durham, NC | ||||
| Amunix Pharmaceuticals | Formerly PE-Backed | South San Francisco, CA | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland |
Elektrofi Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Elektrofi Patents
Elektrofi Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025259911-A1 | Determination of particulate contaminants in particles and compositions | Pending | 12-Jun-2024 | ||
| WO-2025054552-A1 | Particles and suspensions comprising hyaluronan degrading agents and methods of use thereof | Inactive | 08-Sep-2023 | ||
| WO-2023212721-A1 | Injectable suspensions | Inactive | 29-Apr-2022 | ||
| WO-2022256840-A2 | Methods for screening particle formulations comprising proteins | Inactive | 04-Jun-2021 | ||
| WO-2022256840-A3 | Methods for screening particle formulations comprising proteins | Inactive | 04-Jun-2021 | G01N33/6803 |
Elektrofi Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Elektrofi Former Investors (23)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BVF Partners | Hedge Fund | Minority | ||
| Braidwell | Hedge Fund | Minority | ||
| Catalio Capital Management | Venture Capital | Minority | ||
| Charlotte Angel Fund | Angel Group | Minority | ||
| Checkpoint Capital | Hedge Fund | Minority |
Elektrofi FAQs
-
When was Elektrofi founded?
Elektrofi was founded in 2016.
-
Where is Elektrofi headquartered?
Elektrofi is headquartered in Boston, MA.
-
What is the size of Elektrofi?
Elektrofi has 96 total employees.
-
What industry is Elektrofi in?
Elektrofi’s primary industry is Drug Delivery.
-
Is Elektrofi a private or public company?
Elektrofi is a Private company.
-
What is the current valuation of Elektrofi?
The current valuation of Elektrofi is .
-
What is Elektrofi’s current revenue?
The current revenue for Elektrofi is .
-
How much funding has Elektrofi raised over time?
Elektrofi has raised $159M.
-
Who are Elektrofi’s investors?
BVF Partners, Braidwell, Catalio Capital Management, Charlotte Angel Fund, and Checkpoint Capital are 5 of 23 investors who have invested in Elektrofi.
-
Who are Elektrofi’s competitors?
Entos Pharmaceuticals, Lisata Therapeutics, Parion Sciences, Amunix Pharmaceuticals, and CRISPR Therapeutics are some of the 32 competitors of Elektrofi.
-
When was Elektrofi acquired?
Elektrofi was acquired on 18-Nov-2025.
-
Who acquired Elektrofi?
Elektrofi was acquired by Halozyme Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
